Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Declines By 16.2%

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) was the recipient of a large drop in short interest in February. As of February 13th, there was short interest totaling 540,151 shares, a drop of 16.2% from the January 29th total of 644,912 shares. Approximately 1.7% of the shares of the stock are sold short. Based on an average daily volume of 143,301 shares, the days-to-cover ratio is presently 3.8 days. Based on an average daily volume of 143,301 shares, the days-to-cover ratio is presently 3.8 days. Approximately 1.7% of the shares of the stock are sold short.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ ORMP opened at $3.34 on Tuesday. The company has a 50 day simple moving average of $3.31 and a 200 day simple moving average of $2.75. Oramed Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $3.76. The firm has a market cap of $132.93 million, a PE ratio of 2.65 and a beta of 1.31.

Oramed Pharmaceuticals Dividend Announcement

The business also recently disclosed a dividend, which was paid on Monday, January 26th. Investors of record on Friday, January 16th were issued a $0.25 dividend. The ex-dividend date was Friday, January 16th. Oramed Pharmaceuticals’s dividend payout ratio is presently 19.84%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Oramed Pharmaceuticals in a report on Monday, December 29th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the company has a consensus rating of “Hold”.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SB Capital Management Inc bought a new stake in shares of Oramed Pharmaceuticals in the 4th quarter valued at about $5,415,000. XTX Topco Ltd lifted its stake in shares of Oramed Pharmaceuticals by 59.9% in the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 14,297 shares during the period. Quadrature Capital Ltd bought a new stake in Oramed Pharmaceuticals in the fourth quarter valued at approximately $119,000. Squarepoint Ops LLC increased its position in Oramed Pharmaceuticals by 95.1% during the 4th quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 28,406 shares during the period. Finally, Marshall Wace LLP bought a new position in Oramed Pharmaceuticals during the 4th quarter worth approximately $738,000. 12.73% of the stock is owned by institutional investors and hedge funds.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.